The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2003
Filed:
Nov. 22, 2002
Wesley Peter Blackaby, Buckhurst Hill, GB;
Simon Charles Goodacre, Benington, GB;
David James Hallett, Watford, GB;
Andrew Jennings, Sawbridgworth, GB;
Richard Thomas Lewis, Bishop's Stortford, GB;
Kevin William Moore, Buntingford, GB;
Leslie Joseph Street, Little Hallingbury, GB;
Merck Sharp & Dohme Ltd., Hoddesdon, US;
Abstract
A class of 3-phenylimidazo(1,2-a)pyrimidine derivatives (of Formula I, or salt or prodrug thereof: I) wherein Y represents a chemical bond, an oxygen atom, or a —NH— linkage; Z represents an optionally substituted aryl or heteroaryl group; R represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano trifluoromethyl, nitro, —OR , —SR , —SOR , —SO R , —SO NR R , —NR R , —NR COR , —NR CO R , —COR , CO R , —CONR R or —CR ═NOR ; and R and R independently represent hydrogen, hydrocarbon or a heterocyclic group.), substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, are selective ligands for GABA receptors, in particular having good affinity for the a2 and/or a3 and/or a5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.